Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT IV: Ribociclib or Eribulin in HER2-negative MBC
NCT02035813Phase 2Completed
- Sponsor
- Prof. Wolfgang Janni
- Start
- Jan 2014
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib, eribulin in breast cancer, sponsored by Prof. Wolfgang Janni. Started Jan 2014; status: completed.
02
Drugs
ribocicliberibulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02035813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035813.